Gilead Sciences stock forecast for 2030: Can $7.8B Arcellx deal push GILD to $220 with no patent cliff until 2036?

Traders Union
All News
Financial News
GILD Arcellx acquisition Yeztugo

Gilead stock price tests support after pullback from highs

Gilead trades at $148.22, down 0.26%, after retreating from recent peaks around $158. The stock continues in an obvious uptrend that started in early 2025 and has always traded above every major moving average in this period. The 20 EMA is at $147.26, which offers instant support to your bid, and the 50 EMA at $139.79, 100 EMA at $131.72, and 200 EMA at $121.91 all indicate strength in the broader uptrend.

Highlights

Gilead trades at $148.22, consolidating near 20 EMA support after pulling back from $158 highs in a strong uptrend.
Stock could reach $200-240 by 2030 if anito-cel captures CAR T share and Yeztugo scales to $3B with no LOE until 2036.
GILD acquires Arcellx for $7.8B, guides Yeztugo to $800M in 2026 (5x ramp), targets four launches, and posts 6-7% base growth.

GILD price dynamics (Source: TradingView)

The current pullback has pulled the stock back towards the 20 EMA, a standard spot of retest during an uptrend. RSI at 54.80 is neutral after a run of overbuying above 70 it hit on the January-February rally. This ongoing upward move line from 2025 lows offers structural support in the shape of $145-147. Holding above the 20 EMA of $147.26 maintains near-term momentum. The 50 EMA is at $139.79 if the break is under $145. Reclaiming $152-155 opens the way to $160.

Four product launches target 2026

There are 4 expected product launches in 2026. CEO Daniel O’Day said the company is targeting four commercial launches in 2026: Trodelvy for first-line metastatic triple-negative breast cancer, a daily oral combination of bictegravir and lenacapavir for HIV treatment, anito-cel for fourth-line or later relapsed/refractory multiple myeloma, and Bulevirtide in the U.S. for chronic hepatitis delta.

For 2026, Gilead outlined a range of product sales between $29.6 billion and $30.0 billion, with non-GAAP EPS expected to be in the range of $8.45-$8.85. Excluding policy impacts related to drug pricing agreements, Gilead’s base business is expected to grow at 6-7% in 2026. CEO O’Day stressed that without a significant loss of exclusivity until 2036, the next 10 years of Gilead’s operations are safeguarded.

Analyst outlook and valuation path

Analyst Anton Kharitonov observed: “Gilead just paid $7.8 billion for what could become the safer CAR T option in multiple myeloma. Anito-cel's zero parkinsonism cases versus Carvykti's safety issues matters when you're chasing a $1.9 billion market. The real surprise is Yeztugo going from $150 million to $800 million in one year.

Twice-yearly dosing isn't just convenient; it's expanding the market to people who never took daily PrEP pills. Four launches in 2026 is aggressive, but with no patent cliff until 2036, Gilead has time to execute without the usual pharma panic.”

Recently, Gilead consolidated near $148 after acquiring Arcellx for $7.8 billion and guiding Yeztugo to $800 million (5x growth from $150 million), with the stock testing 20 EMA support as investors evaluated whether four 2026 product launches and no patent cliff until 2036 justify the valuation.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.